ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial', International Journal of Cardiology, 395, http://dx.doi.org/10.1016/j.ijcard.2023.131444
,2023, 'Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140b
,2023, 'Canagliflozin Treatment Impact on Collagen Type III Turnover Is Associated with a Reduced Mortality Risk in CANVAS', Journal of the American Society of Nephrology, 34, pp. 136 - 136, http://dx.doi.org/10.1681/asn.20233411s1136a
,2023, 'Criterion validation of nutrient profiling systems: a systematic review and meta-analysis', American Journal of Clinical Nutrition, 119, http://dx.doi.org/10.1016/j.ajcnut.2023.10.013
,2023, 'Iron Biomarkers and Effects of Canagliflozin in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140c
,2023, 'P29-040-23 The Effect of Mycoprotein Intake on Biomarkers of Human Health: A Systematic Review and Meta-Analysis', Current Developments in Nutrition, 7, pp. 101428 - 101428, http://dx.doi.org/10.1016/j.cdnut.2023.101428
,2023, 'S-16-1: RESISTANT HYPERTENISION: CLINICAL CHARACTERISTICS AND BLOOD PRESSURE CONTROL', Journal of Hypertension, 41, pp. e42, http://dx.doi.org/10.1097/01.hjh.0000913112.64878.4e
,2023, 'TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL', Journal of the American College of Cardiology, 81, pp. 283, http://dx.doi.org/10.1016/s0735-1097(23)00727-1
,2022, 'Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial', Cardiovascular Diabetology, 21, pp. 261, http://dx.doi.org/10.1186/s12933-022-01666-7
,2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure', Cardiovascular Diabetology, 21, pp. 194, http://dx.doi.org/10.1186/s12933-022-01619-0
,2022, 'Socio-economic difference in purchases of ultra-processed foods in Australia: an analysis of a nationally representative household grocery purchasing panel', International Journal of Behavioral Nutrition and Physical Activity, 19, pp. 148, http://dx.doi.org/10.1186/s12966-022-01389-8
,2022, 'The effects of government policies targeting ethics and governance processes on clinical trial activity and expenditure: a systematic review', Humanities and Social Sciences Communications, 9, pp. 266, http://dx.doi.org/10.1057/s41599-022-01269-3
,2022, 'Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials', The Lancet, 400, pp. 1788 - 1801, http://dx.doi.org/10.1016/S0140-6736(22)02074-8
,2022, 'Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria', Journal of the American College of Cardiology, 80, pp. 1721 - 1731, http://dx.doi.org/10.1016/j.jacc.2022.08.772
,2022, 'Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS', Diabetes Care, 45, pp. 2644 - 2652, http://dx.doi.org/10.2337/dc22-0866
,2022, 'Testing the Feasibility and Dietary Impact of a “Produce Prescription” Program for Adults with Undermanaged Type 2 Diabetes and Food Insecurity in Australia', Journal of Nutrition, 152, pp. 2409 - 2418, http://dx.doi.org/10.1093/jn/nxac152
,2022, 'Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis', Diabetes, Obesity and Metabolism, 24, pp. 1927 - 1938, http://dx.doi.org/10.1111/dom.14772
,2022, 'Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis', Heart, 108, pp. 1608 - 1615, http://dx.doi.org/10.1136/heartjnl-2022-321332
,2022, 'Estimated Benefits and Risks of Using a Reduced-Sodium, Potassium-Enriched Salt Substitute in India: A Modeling Study', Hypertension, 79, pp. 2188 - 2198, http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19072
,2022, 'Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial', Diabetes, Obesity and Metabolism, 24, pp. 1950 - 1956, http://dx.doi.org/10.1111/dom.14779
,2022, 'Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension – the SaltSwitch Online Grocery Shopping randomized trial', American Heart Journal, 252, pp. 70 - 83, http://dx.doi.org/10.1016/j.ahj.2022.06.007
,2022, 'Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk', Heart Failure Clinics, 18, pp. 645 - 654, http://dx.doi.org/10.1016/j.hfc.2022.03.008
,2022, 'A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease', Kidney360, 3, pp. 1599 - 1602, http://dx.doi.org/10.34067/KID.0002172022
,2022, 'Nation-Wide Routinely Collected Health Datasets in China: A Scoping Review', Public Health Reviews, 43, pp. 1605025, http://dx.doi.org/10.3389/phrs.2022.1605025
,2022, 'Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis', The Lancet Diabetes and Endocrinology, 10, pp. 645 - 654, http://dx.doi.org/10.1016/S2213-8587(22)00172-3
,2022, 'The effects on clinical trial activity of direct funding and taxation policy interventions made by government: A systematic review', PLoS ONE, 17, pp. e0269021, http://dx.doi.org/10.1371/journal.pone.0269021
,2022, 'Effect of voluntary Health Star Rating labels on healthier food purchasing in New Zealand: Longitudinal evidence using representative household purchase data', BMJ Nutrition, Prevention and Health, 5, pp. 227 - 234, http://dx.doi.org/10.1136/bmjnph-2022-000459
,2022, 'Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial', Journal of the American Heart Association, 11, pp. e025045, http://dx.doi.org/10.1161/JAHA.121.025045
,2022, 'Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)', Diabetes Care, 45, pp. 1893 - 1899, http://dx.doi.org/10.2337/dc21-2398
,2022, 'Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE', International Journal of Cardiology, 358, pp. 103 - 109, http://dx.doi.org/10.1016/j.ijcard.2022.04.044
,2022, 'The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial', Diabetes and Metabolism, 48, pp. 101331, http://dx.doi.org/10.1016/j.diabet.2022.101331
,2022, 'Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 24, pp. 1072 - 1083, http://dx.doi.org/10.1111/dom.14671
,2022, 'Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study', Circulation, 145, pp. 1534 - 1541, http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059573
,2022, 'Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials', Circulation, 145, pp. 1460 - 1470, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057736
,2022, 'The sodium hidden in medication: a tough pill to swallow', European Heart Journal, 43, pp. 1756 - 1758, http://dx.doi.org/10.1093/eurheartj/ehab888
,2022, 'Reply to A Coskun and B Oz', Advances in Nutrition, 13, pp. 692 - 693, http://dx.doi.org/10.1093/advances/nmac005
,2022, 'Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin', Journal of the American College of Cardiology, 79, pp. 432 - 444, http://dx.doi.org/10.1016/j.jacc.2021.11.027
,2022, 'Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease', Clinical Journal of the American Society of Nephrology, 17, pp. 251 - 259, http://dx.doi.org/10.2215/CJN.08780621
,2022, 'Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial', American Journal of Kidney Diseases, 79, pp. 244 - 256.e1, http://dx.doi.org/10.1053/j.ajkd.2021.05.005
,2022, 'The Contribution of Major Food Categories and Companies to Household Purchases of Added Sugar in Australia', Journal of the Academy of Nutrition and Dietetics, 122, pp. 345 - 353.e3, http://dx.doi.org/10.1016/j.jand.2021.06.013
,2022, '2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action', Journal of Human Hypertension, 37, http://dx.doi.org/10.1038/s41371-022-00690-0
,2022, 'Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials', Heart, 108, pp. 1281 - 1289, http://dx.doi.org/10.1136/heartjnl-2021-320171
,2022, 'Clinical utility of KidneyIntelX in early stages of diabetic kidney disease in the CANVAS trial', American Journal of Nephrology, 53, pp. 21 - 31, http://dx.doi.org/10.1159/000519920
,2022, 'Erratum: Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China (Global Heart (2021) 16: 1 (47) DOI: 10.5334/gh.913)', Global Heart, 17, pp. 88, http://dx.doi.org/10.5334/GH.1172
,2022, 'Randomized Trials Fit for the 21st Century. A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation', Global Heart, 17, pp. 85, http://dx.doi.org/10.5334/GH.1178
,2022, 'Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials', Hypertension, 79, http://dx.doi.org/10.1161/hyp.79.suppl_1.p201
,2022, 'Testing the Feasibility and Dietary Impact of a "Produce Prescription" Program for Adults with Undermanaged Type 2 Diabetes and Food Insecurity in Australia.', J Nutr, 152, pp. 2409 - 2418, http://dx.doi.org/10.1093/jn/nxac152
,2021, 'Salt Substitute and Cardiovascular Events and Death. Reply', The New England journal of medicine, 385, pp. 2493 - 2494, http://dx.doi.org/10.1056/NEJMc2116824
,2021, 'Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial', European Heart Journal, 42, pp. 4891 - 4901, http://dx.doi.org/10.1093/eurheartj/ehab497
,2021, 'Factors Associated with the Use of a Salt Substitute in Rural China', JAMA Network Open, 4, pp. e2137745, http://dx.doi.org/10.1001/jamanetworkopen.2021.37745
,